Cargando…
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
Cemiplimab is a highly potent, hinge-stabilized human IgG4 monoclonal antibody (mAb) targeting programmed cell death 1 (PD-1) receptor approved for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (SCC) who are not candidates for curative surgery or curative radiation....
Autores principales: | Gambale, Elisabetta, Fancelli, Sara, Caliman, Enrico, Petrella, Maria Cristina, Doni, Laura, Pillozzi, Serena, Antonuzzo, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804682/ https://www.ncbi.nlm.nih.gov/pubmed/35101944 http://dx.doi.org/10.1136/jitc-2021-003540 |
Ejemplares similares
-
Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
por: Paderi, Agnese, et al.
Publicado: (2021) -
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
por: Fancelli, Sara, et al.
Publicado: (2021) -
PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy
por: Lu, Dan, et al.
Publicado: (2022) -
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma
por: Pasqui, Adriano, et al.
Publicado: (2022) -
SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)